Setting Priorities for Diabetic Retinopathy Clinical Research and Identifying Evidence Gaps

Ophthalmology Retina

Volumn 1, Issue 2, 2017, Pages 94-102

  Le, Jimmy T ^a   Hutfless, Susan ^b   Li, Tianjing ^a   Bressler, Neil M ^c   Heyward, James ^a   Bittner, Ava K ^d   Glassman, Adam ^e   Dickersin, Kay ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NOVA SOUTHEASTERN UNIVERSITY   (United States)

^e JAEB CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; VASCULOTROPIN INHIBITOR;

ADOLESCENT; ARTICLE; CLINICAL RESEARCH; CROSS-SECTIONAL STUDY; DELPHI STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; HUMAN; INTRAOCULAR PRESSURE; MALE; MORTALITY; OPTICAL COHERENCE TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 85045567424     PISSN: None     EISSN: 24686530     Source Type: Journal    
DOI: 10.1016/j.oret.2016.10.003     Document Type: Article

References (42)

1. Institute of Medicine, Initial National Priorities for Comparative Effectiveness Research. 2009, Institute of Medicine, Washington DC.
2. Institute of Medicine, Knowing What Works in Health Care: A Roadmap for the Nation. 2008, National Academies Press, Washington, DC.
3. Higgins, J.P.T., Green, S., Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. 2008, Wiley-Blackwell, Chichester, England; Hoboken, NJ.
4. Glasziou, P., Chalmers, I., How systematic reviews can reduce waste in research. BMJ, (eds.) BMJ Blogs, 2016, 2015, BMJ, London.
5. Smith, N., Mitton, C., Peacock, S., et al. Identifying research priorities for health care priority setting: a collaborative effort between managers and researchers. BMC Health Serv Res, 9, 2009, 165.
6. Sox, H.C., Greenfield, S., Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med 151:3 (2009), 203–205.
7. Committee on Comparative Effectiveness Research Prioritization BoHCS, Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. 2009, The National Academies Press, Washington, DC.
8. Nasser, M., Welch, V., Tugwell, P., et al. Ensuring relevance for Cochrane reviews: evaluating processes and methods for prioritizing topics for Cochrane reviews. J Clin Epidemiol 66:5 (2013), 474–482.
9. Saaddine, J.B., Honeycutt, A.A., Narayan, K.M., et al. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Arch Ophthalmol 126:12 (2008), 1740–1747.
10. Li, T., Vedula, S.S., Scherer, R., Dickersin, K., What comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities. Ann Intern Med 156:5 (2012), 367–377.
11. Li, T., Ervin, A.M., Scherer, R., et al. Setting priorities for comparative effectiveness research: a case study using primary open-angle glaucoma. Ophthalmology 117:10 (2010), 1937–1945.
12. Yu, T., Li, T., Lee, K.J., et al. Setting priorities for comparative effectiveness research on management of primary angle closure: a survey of Asia-Pacific clinicians. J Glaucoma 24:5 (2015), 348–355.
13. Ding, J., Wong, T.Y., Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 12:4 (2012), 346–354.
14. Martinez-Zapata, M.J., Marti-Carvajal, A.J., Sola, I., et al. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev, 11, 2014, CD008721.
15. Jampol, L.M., Glassman, A.R., Bressler, N.M., Comparative effectiveness trial for diabetic macular edema: three comparisons for the price of 1 study from the Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol 133:9 (2015), 983–984.
16. Varma, R., Bressler, N.M., Doan, Q.V., et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 132:11 (2014), 1334–1340.
17. Yau, J.W., Rogers, S.L., Kawasaki, R., et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:3 (2012), 556–564.
18. National Eye Institute. Diabetic Retinopathy: Projections for Diabetic Retinopathy. https://nei.nih.gov/eyedata/diabetic. Accessed September 30, 2016.
19. Diabetic Retinopathy Clinical Research Network. General information about the Diabetic Retinopathy Clinical Research Network. 2015. Available at: http://drcrnet.jaeb.org/ViewPage.aspx?PageName=General_Info. Accessed December 9, 2015.
20. American Academy of Ophthalmology Retina/Vitreous Preferred Practice Patterns Panel. Diabetic Retinopathy Preferred Practice Patterns—2012. 2012, American Academy of Ophthalmology, San Francisco, CA.
21. Survey Monkey LLC. Free Online Survey Software & Questionnaire Tool [computer program]. 2015, SurveyMonkey Inc, Palo Alto.
22. Stata Statistical Software: release 14 [computer program], 2015, StataCorp LP, College Station, TX.
23. SAS [computer program], 2011, SAS Institute Inc, Cary, NC.
24. Diabetic Retinopathy Clinical Research Network. DRCR.net Overview. Available at: http://drcrnet.jaeb.org/ViewPage.aspx?PageName=Presentations. Accessed September 30, 2016.
25. Smith, J.M., Steel, D.H., Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev(8), 2015, CD008214.
26. Do, D.V., Wang, X., Vedula, S.S., et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev, 1, 2015, CD006127.
27. Evans, J.R., Michelessi, M., Virgili, G., Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database Syst Rev(11), 2014, CD011234.
28. Virgili, G., Parravano, M., Menchini, F., Evans, J.R., Anti–vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev(10), 2014, CD007419.
29. Lopes de Jesus, C.C., Atallah, A.N., Valente, O., Moca Trevisani, V.F., Pentoxifylline for diabetic retinopathy. Cochrane Database Syst Rev(2), 2008, CD006693.
30. Lopes de Jesus, C.C., Atallah, A.N., Valente, O., Moca Trevisani, V.F., Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy. Cochrane Database Syst Rev(1), 2008, CD006695.
31. Grover, D., Li, T.J., Chong, C.C., Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev(1), 2008, CD005656.
32. Virgili, G., Menchini, F., Casazza, G., et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev, 1, 2015, CD008081.
33. American Academy of Ophthalmology Retina/Vitreous Preferred Practice Patterns Panel, Diabetic Retinopathy Preferred Practice Patterns—2014. 2014, American Academy of Ophthalmology, San Francisco, CA.
34. Lindsley, K., Li, T., Ssemanda, E., et al. Interventions for age-related macular degeneration: are practice guidelines based on systematic reviews?. Ophthalmology 123:4 (2016), 884–897.
35. Elman, M.J., Bressler, N.M., Qin, H., et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118:4 (2011), 609–614.
36. Early Treatment Diabetic Retinopathy Study Group, Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report no. 4. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 27:4 (1987), 265–272.
37. Saldanha, I.J., Dickersin, K., Wang, X., Li, T., Outcomes in Cochrane systematic reviews addressing four common eye conditions: an evaluation of completeness and comparability. PLoS One, 9(10), 2014, e109400.
38. Williamson, P.R., Altman, D.G., Blazeby, J.M., et al. Developing core outcome sets for clinical trials: issues to consider. Trials, 13, 2012, 132.
39. Le, J.T., Viswanathan, S., Tarver, M.E., et al. Assessment of the incorporation of patient-centric outcomes in studies of minimally invasive glaucoma surgical devices. JAMA Ophthalmol 134 (2016), 1054–1056.
40. Asch, D.A., Jedrziewski, M.K., Christakis, N.A., Response rates to mail surveys published in medical journals. J Clin Epidemiol 50:10 (1997), 1129–1136.
41. Creavin, S.T., Creavin, A.L., Mallen, C.D., Do GPs respond to postal questionnaire surveys? A comprehensive review of primary care literature. Fam Pract 28:4 (2011), 461–467.
42. Kellerman, S.E., Herold, J., Physician response to surveys. A review of the literature. Am J Prev Med 20:1 (2001), 61–67.